IP Library Granted Patent US 8,927,543
Granted Patent B2
US 8,927,543 · App. 13/721,788 · Granted Jan 6, 2015

Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Inventors: Frédéric Gilbert Labéguére (Gagny, FR); Gregory John Robert Newsome (Paris, FR); Luke Jonathan Alvey (Versailles, FR); Laurent Raymond Maurice Saniére (Montesson, FR); Stephen Robert Fletcher (Hatfield Heath, GB)
Assignee: Galapagos NV
C07D471/04A61K31/5377A61K45/06A61K31/519
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,927,543
App. No.
13/721,788
Granted
Jan 6, 2015
Kind
B2
Abstract

A compound according to Formula Ia: wherein L 1 , G, and R 1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.

Claims (36)

1. A compound according to Formula IIIa:

wherein

L 1 is absent;

W is C 1-4 alkylene, C 2-4 alkenylene having one double bond, or C 2-4 alkynylene having one triple bond;

L 2 is absent or is —O—;

R 2 is C 3-7 cycloalkyl optionally substituted with one R 5 group,

R 5 is oxo or R 6 ; and

R 6 is selected from OH and C 1-6 alkyl,

or a pharmaceutically acceptable salt, or a solvate, or a solvate of the pharmaceutically acceptable salt thereof.

2. A compound or pharmaceutically acceptable salt thereof, according to claim 1 , wherein W is C 2-4 alkynylene having one triple bond.

3. A compound or pharmaceutically acceptable salt thereof, according to claim 1 , wherein R 2 is C 3-7 cycloalkyl.

4. A compound or pharmaceutically acceptable salt thereof, according to claim 1 , wherein the compound is selected from:

9-Cyclopentylethynyl-2-([1,4]dioxan-2-ylmethoxy)-6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one,

2([1,4]Dioxan-2-ylmethoxy)-9-(1-hydroxy-cyclopentylethynyl)- 6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one,

9-Cyclopentyloxymethyl-2-([1,4]dioxan-2-ylmethoxy)-6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one,

9-Cyclopentyloxymethyl-2-([1,4]dioxan-2-ylmethoxy)-6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one,

9-Cyclopropylethynyl-2-([1,4]dioxan-2-ylmethoxy)-6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one,

9-Cyclopropylethyl-2-((R)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one,

9(2-Cyclopropyl-ethynyl) -2-((R)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one,

9-Cyclopentyloxymethyl-2-((R)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one,

9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one,

9(2-Cyclopropyl-ethyl)-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one,

9-Cyclopentyloxymethyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one,

2-((S)-1-[1,4]Dioxan-2-ylmethoxy)-9-[2-(1-hydroxy-cyclopentyl)-ethyl]-6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one, and

2-((R)-1-[1,4]Dioxan-2-ylmethoxy)-9-[2-(1-hydroxy-cyclopentyl)-ethyl]-6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one.

5. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof, according to claim 1 , and a pharmaceutically acceptable carrier.

6. The pharmaceutical composition according to claim 5 comprising a further therapeutic agent.

7. A compound or pharmaceutically acceptable salt thereof, according to claim 1 , wherein R 2 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

8. A compound or pharmaceutically acceptable salt thereof, according to claim 1 , wherein the compound is according to Formula Va:

wherein R 2 is C 3-7 cycloalkyl optionall substituted with one R 5 group,

R 5 is oxo or R 6 ; and

R 6 is selected from —OH and C 1-6 alkyl.

9. A compound or pharmaceutically acceptable salt thereof, according to claim 1 , wherein the compound is according to Formula Vb:

wherein R 2 is C 3-7 cycloalkyl optionally substituted with one R 5 group;

R 5 is oxo or R 6 ; and

R 6 is selected from —OH and C 1-6 alkyl.

Assignments (4)
CHANGE OF NAME Recorded Jun 4, 2026
From: GALAPAGOS
To: LAKEFRONT BIOTHERAPEUTICS
Reel/Frame 074845/0068 →
RELEASE OF SECURITY INTEREST Recorded Feb 15, 2022
From: GILEAD SCIENCES, INC.
To: GALAPAGOS NV
Reel/Frame 059020/0871 →
SECURITY INTEREST Recorded Aug 23, 2019
From: GALAPAGOS NV
To: GILEAD SCIENCES, INC.
Reel/Frame 050149/0161 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2013
From: LABEGUERE, FREDERIC GILBERT; NEWSOME, GREGORY JOHN ROBERT; ALVEY, LUKE JONATHAN; SANIERE, LAURENT RAYMOND MAURICE; FLETCHER, STEPHEN ROBERT; GALAPAGOS SASU
To: GALAPAGOS NV
Reel/Frame 029879/0541 →
Continuity (2)
Provisional Application 61578979 · Dec 22, 2011
Related Publication 20130165437A1 · Jun 27, 2013